Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22371046 | 0.91 | PIK3CA (0.52) | PIK3CARIPK1 | |
| SCHEMBL30468343 | 0.91 | PIK3CA (0.52) | PIK3CARIPK1 | |
| Lithium Ion SCHEMBL29849231 | 0.90 | PIK3CA (0.49) | PIK3CARIPK1 | |
| SCHEMBL31483039 | 0.84 | PIK3CA (0.61) | PIK3CARIPK1 | |
| SCHEMBL22371135 | 0.83 | PIK3CA (0.69) | PIK3CARIPK1 | |
| SCHEMBL30468366 | 0.83 | PIK3CA (0.69) | PIK3CARIPK1 | |
| Hydrochloric Acid SCHEMBL22371096 | 0.82 | PIK3CA (0.68) | PIK3CARIPK1 | |
| SCHEMBL22397276 | 0.82 | RIPK1 (0.48) | RIPK1 | |
| SCHEMBL22371171 | 0.81 | RIPK1 (0.67) | RIPK1 | |
| SCHEMBL22370955 | 0.81 | RIPK1 (0.66) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566103-B | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3704118-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
| CN-111566103-A | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2020-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | PIK3CA 388/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.